<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report three cases of patients in their eighties who received anti-EGFR antibody mono-therapy as first-line treatment for <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>CASE 1: An 86-year-old woman who received cetuximab after a colostomy for unresectable <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> with synchronous liver and <z:e sem="disease" ids="C0153676" disease_type="Neoplastic Process" abbrv="">lung metastases</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Serum levels of CEA and CA19-9 showed a significant decrease at 2 months, after which they showed a gradual increase </plain></SENT>
<SENT sid="3" pm="."><plain>Computed tomography (CT) revealed a reduction in the <z:e sem="disease" ids="C1527408,C0034885" disease_type="Disease or Syndrome;Neoplastic Process" abbrv="">rectal tumor</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>CASE 2: An 82-year-old woman who received cetuximab for <z:e sem="disease" ids="C0346989" disease_type="Neoplastic Process" abbrv="">peritoneal metastases</z:e> after a transverse colectomy </plain></SENT>
<SENT sid="5" pm="."><plain>Serum levels of CEA and CA19-9 decreased to <z:mpath ids='MPATH_458'>normal</z:mpath> levels at 2 months, and CT imaging revealed disappearance of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> in the peritoneal cavity </plain></SENT>
<SENT sid="6" pm="."><plain>CASE 3: A 79-year-old man who received panitumumab for lung, liver and para-aortic <z:e sem="disease" ids="C0686619" disease_type="Neoplastic Process" abbrv="">lymph node metastases</z:e> after a descending colectomy </plain></SENT>
<SENT sid="7" pm="."><plain>Serum levels of CEA and CA19-9 showed a decrease at 1 month, after which they showed a gradual increase </plain></SENT>
<SENT sid="8" pm="."><plain>No marked change in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> was observed by CT </plain></SENT>
<SENT sid="9" pm="."><plain>No change was observed in performance status or Vulnerable Elders Survey( <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VES</z:e>-13) score, and the effect on overall condition was minimal </plain></SENT>
<SENT sid="10" pm="."><plain>Grade 1-2 acneiform <z:hpo ids='HP_0000988'>skin rash</z:hpo>, <z:hpo ids='HP_0001818'>paronychia</z:hpo>, and desquamation, and grade 2-3 <z:hpo ids='HP_0000958'>dry skin</z:hpo> and <z:e sem="disease" ids="C0033774" disease_type="Disease or Syndrome" abbrv="">pruritis</z:e> were observed </plain></SENT>
<SENT sid="11" pm="."><plain>More precise instructions on measures for dealing with <z:hpo ids='HP_0000988'>skin rash</z:hpo> are necessary to obtain higher drug compliance </plain></SENT>
</text></document>